AVEO Pharmaceuticals Investor Relations Material
Latest events
Q2 2022
AVEO Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from AVEO Pharmaceuticals Inc
Access all reports
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in finding, acquiring, developing and commercializing novel cancer therapeutics for patients. The company´s lead anti-cancer candidate, Tivozanib, is an oral pan-targeted receptor tyrosine kinase inhibitor that AVEO believes may offer therapeutic benefits to adult patients with various types of cancer, including kidney cancer, breast cancer and colon cancer. The company is also developing a biomarker that could enable physicians to identify earlier in treatment those patients who respond favorably or unfavorably to therapy with Tivozanib or other angiogenesis inhibitors.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
AVEO
Country
🇺🇸 United States